Drugs / CTX-471
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03881488 | May 2019 → May 2025 | head and neck cancer, melanoma, mesothelioma, metastatic malignant neoplasm +2 | Compass Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07392957 | Jun 2026 → Jun 2029 expected | glioblastoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07684170 | Sep 2026 → Sep 2028 expected | neuroendocrine carcinoma | Compass Therapeutics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Compass Therapeutics | Results Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting compasstherapeutics.com ↗
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. |
| 2024-11-08 | Compass Therapeutics | Results Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting compasstherapeutics.com ↗
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. |
| 2024-05-23 | Compass Therapeutics | Results Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 compasstherapeutics.com ↗
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors. |
| 2024-04-09 | Compass Therapeutics | Results Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting compasstherapeutics.com ↗
Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471. |
| 2024-02-28 | Compass Therapeutics | Results Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial compasstherapeutics.com ↗
The combination of CTX-8371 and the Compass agonistic anti-CD137 antibody, CTX-471, further increased anti-tumor efficacy in a mouse tumor model |
| 2024-01-05 | Compass Therapeutics | Results Compass Therapeutics Provides Corporate Update compasstherapeutics.com ↗
First, one patient with small cell lung cancer with a previously reported partial response has converted to a complete response, as confirmed by a PET scan, while continuing therapy on CTX-471. |
| 2022-08-01 | Compass Therapeutics | Results Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update compasstherapeutics.com ↗
A fourth partial response (PR) has been reported in the ongoing Phase 1b monotherapy study of CTX-471 (CD137 agonist) in a patient with mesothelioma |
| 2020-03-30 | Compass Therapeutics | Results Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137 compasstherapeutics.com ↗
The paper , “Differentiated Agonist Antibody Targeting CD137 Eradicates Large Tumors without Hepatotoxicity,” was published in the peer-reviewed journal JCI Insight . |
| 2018-11-06 | Compass Therapeutics | Results Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting compasstherapeutics.com ↗
To our knowledge, CTX-471’s preclinical efficacy as a monotherapy in a very large tumor model is unprecedented for an immuno-oncology antibody. |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX-471 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07684170 ↗ |
| Action | Restore | “CTX-471 restores local immune reactivity through activation of costimulatory immune mediators” NCT07392957 ↗ |
| Route | Intravenous | “IV infusion every 2 weeks” NCT03881488 ↗ |